Patrick Trucchio: Terrific. That’s so helpful. Thank you very much and congrats again.
Craig Tooman: Thank you.
Operator: Thank you. We’ll now go to the next question. And your next question comes from the line of Myles Minter from William Blair & Company. Please go ahead.
Unidentified Analyst: Hi. You’ve got Sarah on for Myles. Congrats on the data. And thanks for taking the question. So, from us, can you guys comment on how many patients in each dose group achieved Lp(a) levels below kind of that 120 nanomole per liter and 72 nanomole per liter threshold associated with cardiovascular disease risk? And then just a quick clarification on SLN501. Would you guys look to reacquire those rights back from Mallinckrodt like you guys have done with some of those other assets, or do you guys kind of feel like you’re good on the complement, targeting assets at the moment with what you’ve currently got? Thanks.
Craig Tooman: So let me again go in reverse order and just say for 501, again, from that portfolio review that we took upon ourselves before we brought the two assets in. We really like those for the size of Silence and the competitive arena that it is in and made that determination when we brought those two in-house. So, no further expectation on that. And Steve, in terms of the segregation data, not sure quite what we can say without query, but up to you.
Steven Romano: Yes. No, unfortunately, we can’t share that information yet. We’ll certainly — we need to preserve some of those details obviously for a presentation at a research meeting, which we’ll do later on this year, hopefully by the end of summer. So we’ll share that information in much more detail over the coming months.
Unidentified Analyst: Excellent. Thank you.
Craig Tooman: Thanks, Sarah.
Operator: Thank you. [Operator Instructions] And your next question comes from the line of Keay Nakae from Chardan. Please go ahead.
Keay Nakae: Yes. Thanks. So in terms of the scientific meeting to present the data, should we guess that could be EFC?
Craig Tooman: Yes, that would be a reasonable expectation. So we’ll confirm that in the near future.
Keay Nakae: Okay, great. And then when we think about the guidance on the runway into 2026, what does that include in terms of commencing a Phase 3?
Craig Tooman: Rhonda?
Rhonda Hellums: Yes. Hi. So that does assume that we would kick that off, and we would continue to prep for that. Again, that does include some of our current collaboration programs. We do anticipate some additional milestones from that, so that is included in our runway as well. And again, we continue to look for any partnering opportunities that will, of course, extend that runway further with the non-dilutive funding first. But that does assume that we would kick off a Phase 3.
Keay Nakae: Okay. Alright. Very good. Thank you.
Craig Tooman: Thank you.
Operator: Thank you. There are currently no further questions. I will hand the call back to Craig for closing remarks.
Craig Tooman: Well, thank you all for joining us on this call. I’m extremely proud of our 2023 performance and overall results. As I mentioned at the beginning of this call, 2023 set us up for what we expect to be a very data rich year. And with that building recognition of Silence as a true platform company, we look forward to keeping you updated on our progress. Thank you and have a great day.
Operator: Thank you. This concludes today’s conference call. Thank you for participating. You may now disconnect.
